-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*Only for medical professionals to read for reference.
2021 American Society of Clinical Oncology (ASCO) Annual Meeting will be held online from June 4th to June 8th
.
This ASCO annual meeting received a total of more than 5,400 research abstract submissions from around the world.
Two research results from Professor Hu Chunhong and Associate Professor Wu Fang from the Cancer Center of the Second Xiangya Hospital of Central South University stood out and were selected for display in the conference poster
.
The American Society of Clinical Oncology (ASCO) was established in 1964 and is the world's largest and most influential academic organization for oncology
.
The society has more than 45,000 members from more than 150 countries who specialize in oncology
.
The annual ASCO annual meeting is a grand ceremony of global oncology academics.
It gathers experts in the field of oncology from all over the world.
Many cutting-edge oncology research results will be released at the ASCO annual meeting
.
The theme of 2021 ASCO is: "Equity: Every Patient
.
Every Day.
Everywhere" .
A postoperative recurrence of non-small cell lung cancer related genes and tumor immune microenvironment characteristics.
With the popularization of CT screening, more and more stage I NSCLC have been discovered and undergoing surgical resection
.
Even with stage I NSCLC, nearly half of patients still have recurrence and metastasis within five years
.
At present, the mechanism of postoperative recurrence and metastasis of stage I NSCLC is not clear, and there is a lack of effective adjuvant treatments in the perioperative period
.
How do tumor gene mutations and immune microenvironment status jointly affect postoperative recurrence and metastasis of stage I NSCLC? In this study, by detecting the gene mutation status and immune microenvironment characteristics of 130 patients with stage I NSCLC, and analyzing its impact on tumor recurrence and metastasis, this study provides a new idea for the study of the recurrence mechanism and clinical transformation of stage I NSCLC
.
A network meta-analysis of first-line immunotherapy strategies for the second-driver gene-negative NSCLC populations in each subgroup.
Immunotherapy (immune checkpoint inhibitors) is the standard treatment for driver-gene-negative advanced non-small cell lung cancer
.
A number of clinical randomized controlled trials (RCT) have proved that immune checkpoint inhibitors are better than traditional chemotherapy in patients with advanced non-small cell lung cancer, but for patients with different clinicopathological characteristics, such as different gender, age, smoking status, and metastasis Does the site, histological type, and PD-L1 expression require different immunotherapy monotherapy or combination therapy strategies? This network meta-analysis compares the pros and cons of 10 immunotherapy strategies among 19 NSCLC subgroups, and finds the best immunotherapy strategies for NSCLC patients with different clinicopathological characteristics
.
The team of Professor Chunhong Hu and Associate Professor Wu Fang has been committed to clinical and translational research related to lung cancer targeted and immunotherapy
.
The team has received a number of grants from the National Natural Science Foundation of China and Hunan Youqing, etc.
, has published many papers in journals such as Lancet Oncology, and won one second prize for scientific and technological progress in Hunan Province
.
The two research results selected for the 2021ASCO annual meeting respond to the theme of this annual meeting and once again reflect the team's long-term adherence to the research direction, demonstrating the team spirit of being patient, innovative, tireless, and persevering
.
Expert profileProfessor Hu Chunhong/first-level chief physician Director of Cancer Research Office, Cancer Center, Xiangya Second Hospital, Central South University, Vice Chairman, Precision Medicine and Tumor Rehabilitation Professional Committee, China Rehabilitation Technology Transformation and Development Promotion Association, China Research Hospital Association, Precision Medicine and Tumor MDT Committee Standing Committee Member, Chinese Research Hospital Association Precision Medicine and Tumor MDT Professional Committee, Central Tumor Clinical Collaboration Group Leader, Chinese Anti-Cancer Association Tumor Chemotherapy Professional Committee Member, Chinese Society of Clinical Oncology Council Member, Hunan Medical Doctor Association Cancer Branch Chairman, Hunan Medical Association Chemotherapy Vice Chairman of the Professional Committee Vice Chairman of the Oncology Committee of the Hunan Society of Integrated Chinese and Western Medicine Vice Chairman of the Oncology Pathology Committee of the Hunan Pathological Society Vice Chairman of the Hunan Anticancer Association Executive Director of the Hunan Anticancer Association Vice Chairman of the Lung Cancer Professional Committee of the Hunan Anticancer Association Chemotherapy Major of the Hunan Medical Association Introduction to the Experts of the Leader of the Molecular Targeting Group of the Committee Associate Professor Wu Fang Associate Professor Xiangya Second Xiangya Hospital Tumor Center Associate Professor Master Student Supervisor, Xiangya Second Xiangya Hospital, Central South University Associate Professor, Master Student Supervisor, Central South University Xiangya Second Hospital Scientific Research Department Director of Tumor Big Data Intelligent Application Hunan Deputy Director of the Provincial Engineering Research Center, Hunan Youqing, Member of the Multidisciplinary Cancer Diagnosis and Treatment (MDT) Professional Committee of the Chinese Medical Doctor Association, Member of the Standing Committee of the Chinese Society of Clinical Oncology (csco) Young Expert Committee, Member of the Chinese Society of Clinical Oncology (csco) Non-small Cell Lung Cancer Specialty Committee Deputy Chairman of the Lung Cancer Expert Committee of the Telemedicine and Internet Medical Center, Deputy Chairman of the Youth Committee of the Oncology Rehabilitation and Palliative Care Committee of the Hunan Medical Association, Youth Committee and Secretary of the Oncology Branch of the Hunan Medical Association, Member of the Standing Committee of the Lung Cancer Professional Committee of the Hunan Anti-Cancer Association The first/corresponding author published a paper in journals such as Lancet Oncology.
The American Society of Clinical Oncology (AscO) oral report presided over more than ten reference materials for national, provincial and ministerial projects: [1] Wu F, Tian WT, Cao CH, et al.
Subgroup-level network meta-analysis for efficacy of first-line immunotherapy-based treatments in advanced non-small cell lung cancer.
J Clin Oncol 39,2021(suppl 15;abstr 9064).
https://meetinglibrary.
asco.
org/ record/200500/abstract[2]Wu F,Chunhong Hu,Long Shu,et al.
Identification of recurrence-associated gene signature and tumor immune microenvironment features in resected stage I NSCLC.
J Clin Oncol 39,2021(suppl 15;abstr 9080).
https://meetinglibrary.
asco.
org /record/200469/abstract
2021 American Society of Clinical Oncology (ASCO) Annual Meeting will be held online from June 4th to June 8th
.
This ASCO annual meeting received a total of more than 5,400 research abstract submissions from around the world.
Two research results from Professor Hu Chunhong and Associate Professor Wu Fang from the Cancer Center of the Second Xiangya Hospital of Central South University stood out and were selected for display in the conference poster
.
The American Society of Clinical Oncology (ASCO) was established in 1964 and is the world's largest and most influential academic organization for oncology
.
The society has more than 45,000 members from more than 150 countries who specialize in oncology
.
The annual ASCO annual meeting is a grand ceremony of global oncology academics.
It gathers experts in the field of oncology from all over the world.
Many cutting-edge oncology research results will be released at the ASCO annual meeting
.
The theme of 2021 ASCO is: "Equity: Every Patient
.
Every Day.
Everywhere" .
A postoperative recurrence of non-small cell lung cancer related genes and tumor immune microenvironment characteristics.
With the popularization of CT screening, more and more stage I NSCLC have been discovered and undergoing surgical resection
.
Even with stage I NSCLC, nearly half of patients still have recurrence and metastasis within five years
.
At present, the mechanism of postoperative recurrence and metastasis of stage I NSCLC is not clear, and there is a lack of effective adjuvant treatments in the perioperative period
.
How do tumor gene mutations and immune microenvironment status jointly affect postoperative recurrence and metastasis of stage I NSCLC? In this study, by detecting the gene mutation status and immune microenvironment characteristics of 130 patients with stage I NSCLC, and analyzing its impact on tumor recurrence and metastasis, this study provides a new idea for the study of the recurrence mechanism and clinical transformation of stage I NSCLC
.
A network meta-analysis of first-line immunotherapy strategies for the second-driver gene-negative NSCLC populations in each subgroup.
Immunotherapy (immune checkpoint inhibitors) is the standard treatment for driver-gene-negative advanced non-small cell lung cancer
.
A number of clinical randomized controlled trials (RCT) have proved that immune checkpoint inhibitors are better than traditional chemotherapy in patients with advanced non-small cell lung cancer, but for patients with different clinicopathological characteristics, such as different gender, age, smoking status, and metastasis Does the site, histological type, and PD-L1 expression require different immunotherapy monotherapy or combination therapy strategies? This network meta-analysis compares the pros and cons of 10 immunotherapy strategies among 19 NSCLC subgroups, and finds the best immunotherapy strategies for NSCLC patients with different clinicopathological characteristics
.
The team of Professor Chunhong Hu and Associate Professor Wu Fang has been committed to clinical and translational research related to lung cancer targeted and immunotherapy
.
The team has received a number of grants from the National Natural Science Foundation of China and Hunan Youqing, etc.
, has published many papers in journals such as Lancet Oncology, and won one second prize for scientific and technological progress in Hunan Province
.
The two research results selected for the 2021ASCO annual meeting respond to the theme of this annual meeting and once again reflect the team's long-term adherence to the research direction, demonstrating the team spirit of being patient, innovative, tireless, and persevering
.
Expert profileProfessor Hu Chunhong/first-level chief physician Director of Cancer Research Office, Cancer Center, Xiangya Second Hospital, Central South University, Vice Chairman, Precision Medicine and Tumor Rehabilitation Professional Committee, China Rehabilitation Technology Transformation and Development Promotion Association, China Research Hospital Association, Precision Medicine and Tumor MDT Committee Standing Committee Member, Chinese Research Hospital Association Precision Medicine and Tumor MDT Professional Committee, Central Tumor Clinical Collaboration Group Leader, Chinese Anti-Cancer Association Tumor Chemotherapy Professional Committee Member, Chinese Society of Clinical Oncology Council Member, Hunan Medical Doctor Association Cancer Branch Chairman, Hunan Medical Association Chemotherapy Vice Chairman of the Professional Committee Vice Chairman of the Oncology Committee of the Hunan Society of Integrated Chinese and Western Medicine Vice Chairman of the Oncology Pathology Committee of the Hunan Pathological Society Vice Chairman of the Hunan Anticancer Association Executive Director of the Hunan Anticancer Association Vice Chairman of the Lung Cancer Professional Committee of the Hunan Anticancer Association Chemotherapy Major of the Hunan Medical Association Introduction to the Experts of the Leader of the Molecular Targeting Group of the Committee Associate Professor Wu Fang Associate Professor Xiangya Second Xiangya Hospital Tumor Center Associate Professor Master Student Supervisor, Xiangya Second Xiangya Hospital, Central South University Associate Professor, Master Student Supervisor, Central South University Xiangya Second Hospital Scientific Research Department Director of Tumor Big Data Intelligent Application Hunan Deputy Director of the Provincial Engineering Research Center, Hunan Youqing, Member of the Multidisciplinary Cancer Diagnosis and Treatment (MDT) Professional Committee of the Chinese Medical Doctor Association, Member of the Standing Committee of the Chinese Society of Clinical Oncology (csco) Young Expert Committee, Member of the Chinese Society of Clinical Oncology (csco) Non-small Cell Lung Cancer Specialty Committee Deputy Chairman of the Lung Cancer Expert Committee of the Telemedicine and Internet Medical Center, Deputy Chairman of the Youth Committee of the Oncology Rehabilitation and Palliative Care Committee of the Hunan Medical Association, Youth Committee and Secretary of the Oncology Branch of the Hunan Medical Association, Member of the Standing Committee of the Lung Cancer Professional Committee of the Hunan Anti-Cancer Association The first/corresponding author published a paper in journals such as Lancet Oncology.
The American Society of Clinical Oncology (AscO) oral report presided over more than ten reference materials for national, provincial and ministerial projects: [1] Wu F, Tian WT, Cao CH, et al.
Subgroup-level network meta-analysis for efficacy of first-line immunotherapy-based treatments in advanced non-small cell lung cancer.
J Clin Oncol 39,2021(suppl 15;abstr 9064).
https://meetinglibrary.
asco.
org/ record/200500/abstract[2]Wu F,Chunhong Hu,Long Shu,et al.
Identification of recurrence-associated gene signature and tumor immune microenvironment features in resected stage I NSCLC.
J Clin Oncol 39,2021(suppl 15;abstr 9080).
https://meetinglibrary.
asco.
org /record/200469/abstract
